<DOC>
	<DOCNO>NCT00770653</DOCNO>
	<brief_summary>The purpose study compare pioglitazone metformin combination therapy , twice daily ( BID ) , glimepiride metformin combination therapy treat diabetic subject dyslipidemia .</brief_summary>
	<brief_title>Efficacy Pioglitazone/Metformin Combination Therapy Subjects With Type 2 Diabetes Mellitus Dyslipidemia .</brief_title>
	<detailed_description>Insulin resistance major endocrinopathy precede development hyperglycemia , diabetic dyslipidemia cardiovascular disease type 2 diabetes . The common pattern dyslipidemia patient type 2 diabetes elevate triglyceride level , decrease hih-density lipoprotein cholesterol predominance small dense low-density lipoprotein particle . Each dyslipidemia feature associate increased risk cardiovascular event . Pioglitazone Metformin establish drug use treatment type 2 diabetes . This study investigate effect treatment fix Pioglitazone/Metformin combination therapy Metformin Glimepiride Metformin-pretreated type 2 diabetic patient dyslipidemia . Total participation time study anticipate approximately 24 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes accord American Diabetes Association Criteria . Treatment individual maximal tolerate dose metformin ( 850 2000 mg ) monotherapy within last 12 week . Glycosylated Hemoglobin great equal 6.5 % less equal 9 % . Dyslipidemia define highdensity lipoprotein cholesterol less equal 1.03 mmol/l ( 40 mg/dL ) and/or triglyceride great equal 1.7 mmol/l ( 150 mg/dL ) . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Type 1 diabetes mellitus . Insulindependent type 2 diabetes mellitus . Treatment history treatment insulin formulation emergency 2 week . Treatment oral antidiabetic drug addition metformin within last 12 week . Anamnestic history hypersensitivity study drug drug similar chemical structure . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Heparin ( heparinlike drug ) coumarin phenprocoumon hirudin Protein C Fondaparinux antithrombin III Peroxisome Proliferation Activating Receptor ( gamma ) agonists Treatment within last 12 week : fibrates gemfibrozil niacin month Rifampicin Changes dosage statin treatment low lowdensity lipoprotein within 2 week study entry study participation interval . Changes dosage anticoagulant treatment acetyl salicylic acid and/or clopidogrel within 2 week study entry study participation interval . Start statin and/or anticoagulant treatment study participation interval . History severe multiple allergy and/ acute severe infection . Have one unexplained episode severe hypoglycemia ( define require assistance another person due disable hypoglycemia ) within 6 month prior screen visit . Progressive fatal disease . Any elective surgery study participation . History drug alcohol abuse within last 5 year . A history significant cardiovascular ( New York Heart Association stage I IV ) , respiratory , gastrointestinal , hepatic ( alanine aminotransferase and/or aspartate aminotransferase great 2.5 time upper limit normal reference range ) , renal ( serum creatinine great 1.2 mg/dL woman great 1.5 mg/dL men , glomerular filtration rate le 60 ml/min estimate CockroftGault formula ) , neurological , psychiatric and/or hematological disease judge investigator , history macular edema . Blood donation within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus , Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Hyperlipidemias</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>